Beyond direct phagocytosis, CAR-Ms enhance adaptive immunity through antigen cross-presentation and CD8+ T cell priming, while their shorter in vivo persistence reduces off-tumor toxicity risks. This evidence concerns the gene CD8A and neoplasm.